Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

BACKGROUND: New treatments have improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a distinct mechanism of action; it targets BCL2, a protein central to the survival of CLL cells. METHODS: We conducted a phase 1 do...

Full description

Saved in:

Bibliographic Details
Published in:	N Engl J Med
Main Authors:	Roberts, Andrew W., Davids, Matthew S., Pagel, John M., Kahl, Brad S., Puvvada, Soham D., Gerecitano, John F., Kipps, Thomas J., Anderson, Mary Ann, Brown, Jennifer R., Gressick, Lori, Wong, Shekman, Dunbar, Martin, Zhu, Ming, Desai, Monali B., Cerri, Elisa, Enschede, Sari Heitner, Humerickhouse, Rod A., Wierda, William G., Seymour, John F.
Format:	Artigo
Language:	Inglês
Published:	2015
Subjects:	Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC7107002/ https://ncbi.nlm.nih.gov/pubmed/26639348 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1513257
Tags:	Add Tag No Tags, Be the first to tag this record!

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Similar Items